Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.64 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | SIK1 | P57059 | 3/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 3/20 | 0.43 |
| ▸ | SIK3 | Q9Y2K2 | 3/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294327 | 0.88 | HDAC2 (0.62) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL4474097 | 0.88 | HDAC2 (0.62) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL5321500 | 0.86 | SCD (0.49) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL4818519 | 0.85 | HRH3 (0.50) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL4161740 | 0.83 | HDAC2 (0.74) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL4170065 | 0.83 | HDAC4 (0.69) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL4198413 | 0.80 | HDAC4 (0.71) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL14164269 | 0.78 | HDAC2 (1.00) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL4814015 | 0.78 | HDAC2 (0.69) | HDAC6HDAC2HDAC3HDAC4HDAC1 | |
| SCHEMBL4191552 | 0.77 | HDAC3 (0.67) | HDAC6HDAC2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | claimed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | claimed |
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | claimed |
| US-20090203010-A1 | MSMB-gene based diagnosis, staging and prognosis of prostate cancer | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009089598-A2 | MSMB-GENE METHYLATION BASED DIAGNOSIS, STAGING AND PROGNOSIS OF PROSTATE CANCER | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2009-07-23 | — | — | WO | disclosed |
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | disclosed |
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | disclosed |
| US-7345043-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345043-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1755601-A2 | INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | disclosed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885HDAC2 5/4885HDAC3 6/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885HDAC2 5/4885HDAC3 6/4885 |
| US-20050234033-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885HDAC2 5/4885HDAC3 6/4885 |
| US-20090203010-A1 | MSMB-gene based diagnosis, staging and prognosis of prostate cancer | MAT2B, DNMT3B, SHBG | HDAC6 4661/4885HDAC2 3643/4885HDAC3 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.